Zobrazeno 1 - 10
of 27
pro vyhledávání: '"T P, Sahoo"'
Autor:
M Singhal, T P Sahoo, S Aggarwal, A Singhvi, V Kaushal, S Rajpurohit, K M Parthasarthi, A Vora, M Ganvir, S Gupta, Purvish M Parikh
Publikováno v:
South Asian Journal of Cancer, Vol 7, Iss 2, Pp 151-155 (2018)
Substantial survival benefits exist for patients with early-stage breast cancer who undergo treatment with single-modality ovarian suppression, but its value is uncertain. Expert oncologist discussed to determine whether additional benefits exist wit
Externí odkaz:
https://doaj.org/article/8c6fc7d6195f485ea8be93c4351f1385
Autor:
A. F. M. Kamaluddin, R. P. Baral, Kshitij Joshi, Vamshi Krishna, Akhil Kapoor, Amit Bhatt, Zeba Aziz, G. Biswas, Purvish Parikh, Randeep Singh, K Govind Babu, T. P. Sahoo, Indu Bansal, Raja Thirumalairaj
Publikováno v:
International Journal of Molecular & Immuno Oncology. 6:61-65
Objectives: We present the survey data on molecular testing and its implications among lung cancer specialists in the South Asian Association for Regional Cooperation (SAARC) region. Material and Methods: An online survey Google form was developed th
Autor:
Vamshi Muddu, T. P. Sahoo, Bivas Biswas, Mithua Ghosh, Ashok K. Vaid, Suresh H. Advani, Ullas Batra, Anuradha Chougule, Kumar Prabhash
Publikováno v:
Advances in Therapy. 36:766-785
Novel molecular targets and promising targeted therapies have reshaped diagnostics in patients with advanced non-small cell lung cancer (NSCLC). Despite this progress, the implementation of molecular screening to identify predictive biomarkers in Ind
Autor:
S Rajpurohit, KM Parthasarthi, A. Vora, T. P. Sahoo, S Gupta, A Singhvi, M Ganvir, Purvish M. Parikh, S Aggarwal, Manish Singhal, V. Kaushal
Publikováno v:
South Asian Journal of Cancer, Vol 7, Iss 2, Pp 151-155 (2018)
South Asian Journal of Cancer
South Asian Journal of Cancer
Substantial survival benefits exist for patients with early-stage breast cancer who undergo treatment with single-modality ovarian suppression, but its value is uncertain. Expert oncologist discussed to determine whether additional benefits exist wit
Autor:
Shekar Patil, Raju Titus Chacko, Rajesh Naik, M V Chandrakant, Deepak Dabkara, Shyam Aggarwal, Dinesh Chandra Doval, Chirag Desai, Sohit Anand, Ashok K. Vaid, Shailesh Arjun Bondarde, Kumar Prabhash, Senthil Rajappa, Purvish M. Parikh, Palanki Satya Dattatreya, T. P. Sahoo, Vanita Noronha, G. Biswas, Vijay Patil, Pratap Kishore Das, Amit Joshi
Publikováno v:
South Asian Journal of Cancer
South Asian Journal of Cancer, Vol 7, Iss 3, Pp 203-206 (2018)
South Asian Journal of Cancer, Vol 7, Iss 3, Pp 203-206 (2018)
Background: We conducted a survey of 111 medical oncologists across India to understand the current pattern of epidermal growth factor receptor (EGFR) mutation testing at their respective centers. Methods: Medical oncologists from 111 institutes acro
Autor:
Vineet Talwar, Pritish Gandhi, Ankur Bahl, T. P. Sahoo, Karishma Jhaveri, Purvish M. Parikh, Sudeep Shreshta, Randeep Singh
Publikováno v:
International Journal of Molecular and Immuno Oncology. 4:6-8
Novel immuno-oncology medications are a new addition to the armamentarium in the fight against cancer. This new class of drugs have unique toxicities whose understanding is constantly evolving. Today more is published in scientific literature every y
Autor:
Kumar, Prabhash, Suresh H, Advani, Ullas, Batra, Bivas, Biswas, Anuradha, Chougule, Mithua, Ghosh, Vamshi Krishna, Muddu, T P, Sahoo, Ashok K, Vaid
Publikováno v:
Advances in therapy. 36(4)
Novel molecular targets and promising targeted therapies have reshaped diagnostics in patients with advanced non-small cell lung cancer (NSCLC). Despite this progress, the implementation of molecular screening to identify predictive biomarkers in Ind
Autor:
Narayanankutty Warrier, Vijay Patil, Adwaita Gore, Govind Babu, Shekhar Patil, Nirmal Vivek Raut, Kumar Prabhash, Nitesh Rohatgi, Amish Vora, Bharat Bhosale, Shailesh Arjun Bondarde, Vanita Noronha, T. P. Sahoo, Sewanti Limaye, Bharat Vaswani, Ullas Batra
Publikováno v:
Cancer Research, Statistics, and Treatment. 4:279
The management of patients with advanced non-small-cell lung cancer (NSCLC) is becoming increasingly complex, with the identification of driver mutations/rearrangements and the development and availability of appropriate targeted therapies. In 2018,
Autor:
Hemant Malhotra, P N Mahapatra, Chanchal Goswami, Chirag Shah, Pavithran Keechilat, Suresh H. Advani, T. P. Sahoo, Maheboob Basade, Raju Titus Chacko
Publikováno v:
Indian journal of cancer. 54
Advanced nonsmall cell lung cancer (NSCLC) treatment is primarily based on platinum-based chemotherapy. Although epidermal growth factor receptor (EGFR) targeting has shifted the treatment paradigm toward personalized tyrosine kinase inhibitors (TKIs
Publikováno v:
Indian Journal of Cancer. 56:23
Non-small cell lung cancer (NSCLC) is a major subtype of lung cancer. Patients with NSCLC are diagnosed at a locally advanced or metastatic stage where prognosis with palliative chemotherapy is poor. The discovery of epidermal growth factor receptor